Preface -- PART I HEALTHCARE AND PHARMACEUTICALS: INNOVATION AND REGULATION IN JAPAN -- Regulation and Competition in the Pharmaceutical Industry in Japan -- Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Declining Population -- Drug Regulation in Japan -- Collaboration between the Patent System and Pharmaceutical Regulations for Drug-discovery Innovation in Japan -- Corruption and Conflicts of Interest in the Pharmaceutical Market: Regulation of Pharmaceutical Companies Gift-giving Practices -- PART II THE JAPANESE ANTIMONOPOLY ACT AND ITS RELATION TO THE PHARMACEUTICAL INDUSTRY -- Antimonopoly Act and Its Application to the Pharmaceutical Industry in Japan -- Horizontal Cooperation and Alliances amongst Pharmaceutical Companies and the Japanese Antimonopoly Act -- Merger Regulations in the Japanese Pharmaceutical Industry -- Pay-for-delay Agreements in Japan -- No Challenge Clauses in the Pharmaceutical Industry in Japan -- Will Authorised Biologics deter Biosimilars? -Utilising JFTCs expertise in drug pricing -- PART III AN ECONOMIC ANALYSIS OF THE PHARMACEUTICAL INDUSTRY AND TRADE PRACTICES IN JAPAN -- The Pharmaceutical Industry in Japan: A History of Its Development -- Trade Practices in the Japanese Pharmaceutical Market: A Simulation Analysis of Improvement Policies.
Summary:
This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States. Japan is one of the biggest pharmaceutical markets in the world. With this in mind, the book provides one-stop shopping for anyone interested in pharmaceutical regulations in the country. Covering the basics but extending to in-depth explorations of complex problems, this book appeals not only to students and academics, pharmaceutical companies and regulators, but also to those dealing with real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation. Chapter 11 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
Series:
Kobe University monograph series in social science research
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.